Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

Author:

Chung Hyun Cheol1,Lopez-Martin Jose A.2,Kao Stephen Chuan-Hao3,Miller Wilson H.4,Ros Willeke5,Gao Bo6,Marabelle Aurelien7,Gottfried Maya8,Zer Alona9,Delord Jean-Pierre10,Penel Nicolas11,Jalal Shadia Ibrahim12,Xu Lei13,Zeigenfuss Susan13,Pruitt Scott K.14,Piha-Paul Sarina Anne15

Affiliation:

1. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of (South);

2. Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain;

3. Chris O'Brien Lifehouse, Sydney, Australia;

4. Segal Cancer Center, Jewish General Hospital, Rossy Cancer Network, McGill University, Montreal, QC, Canada;

5. Netherlands Cancer Institute, Amsterdam, Netherlands;

6. Blacktown Hospital, Sydney, Australia;

7. Département d’Innovation Thérapeutique et d’Essais Précoces, Gustave Roussy, Villejuif, France;

8. Lung Cancer Unit, Meir Medical Center, Kfar-Saba, Israel;

9. Rabin Medical Center, Petah Tikva, Israel;

10. Department of Oncology, Institut Claudius Regaud Institut Universitaire du Cancer-Oncopole, Toulouse, France;

11. Oscar Lambret Cancer Center, Lille, France;

12. Indiana University, Simon Cancer Center, Indianapolis, IN;

13. Merck & Co., Inc., Upper Gwynedd, PA;

14. Merck & Co., Inc., Rahway, NJ;

15. The University of Texas MD Anderson Cancer Center, Houston, TX;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3